Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (5953)	11/28/2000 11:58:20 PM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

BJ, Peter had said this was the way they were going. They said they were looking at a number of companies and felt they would split Europe up. At that time he mentioned Germany, France, Italy, Spain, and I forget the fifth country. Now it appears they're going richest first which my searches a couple of months ago agree with. I believe that's why Spain has apparently been replaced by Sweden. What troubles me is that Switzerland is not part of the EU. The European Union is: Austria Belgium Denmark Finland France Germany Greece Ireland Italy Luxembourg Netherlands Portugal Spain Sweden United Kingdom of Great Britain and Northern Ireland She said in the DJN interview: In a news release, Dimethaid said it will immediately seek approvals for PENNSAID from other European Union countries. Under the mutual recognition procedure prevailing in the EU, the U.K. will act as agent for other EU member states, who can recognize this approval and issue their own authorizations. "Because the British regulatory agency is so well-recognized in Europe, we don't anticipate any negative responses when they submit on our behalf to the other countries," Keeler said, noting that submissions for approval will be made in January to Germany, France, Italy, Sweden and Switzerland, with other European countries to follow. Submissions in January. We could have a good collection of these by May. I estimated Germany and France together as 3 times the size of the British market. Between them they have a population just below 150 million people with rich medical coverage. As Peter said, of the finalists in the negotiations, they would probably pick a UK partner and a european partner. How they actually end up slicing the pie I'm not sure, but, its unlikely we won't get at least 2 partners out of this round of negotiations. Mathematically, the UK at around 55 million plus is a 600 million dollar market (Peter had said 20% was topical) and the other big two should bring that up to around 2.4 billion Cdn (euro is lower but medical spending is richer). Should be plenty of opportunity for sales growth hopefully beginning in March, but looking good for the summer. Going head to head with the oral's I hope refers to sales effort and not labelling limitation. I don't see that. As Pennsaid establishes that it truly works (and works well), it should naturally start encroaching on Oral NSAID sales. We've been waiting for the revenue game for a long time, and I am looking forward to early 2002 calendar, when EPS drive this stock past where I need it regardless of analysts and their piniata predictions. To all, Further to my comments on portfolio returns which John replied to - I came in in 1998. A compounded 50% rate of return on that would be a $26 stock price June 02, 2002. As I've been saying all along, I expect much more. The high dollar buy's were all this year and so will also exceed that rate if I see that price by that date. Investors need to decide what they're measuring. That's both values and timelines. If you haven't, write down on a piece of paper what you expect and by when. Then ask yourself how probable that is. Once you get a number you also feel is probable by your date, stop watching the stock price and concentrate on understanding the story and events better. (Of course that's more for longer term investors). This promotes good kharma. We're a year late. Yup. And I can live with that. Everybody has their own style. Mine is very long term. (I wasn't kidding Mark/Olga). Wolf

To: DaveAu who wrote (5953)	11/29/2000 12:32:30 AM
From: Joe Krupa	Read Replies (2) \| Respond to of 14101

Hi Dave, "It's also sounding like they're not trying to go head to head with the oral NSAIDS, at least initially. They're targeting the other topicals and the people with kidney and G.I. problems." Could this possibly be good politicking by Dimethaid, until all approvals are in, particularly the FDA? I think we have all been made keenly aware lately (read HPB) that good politics is an essential tactic in seeking regulatory approval. An all out PR/marketing assault on the oral NSAID market might not sit well with the egos that be at Celebrex or Vioxx. It could possibly intensify political pressure against Pennsaid in other countries who have not yet approved. Dimethaid knows Pennsaid will eventually take a chunk out of the oral NSAID market, so why rub it in their faces (no pun intended) off the get go? Why risk it? I say, let's be the well behaved new kid on the block until we are in a better position to unleash the full PR machine. Just some late night thoughts. Joe